first-in-human study

Up to a certain moment, everything known about a candidate drug comes from test tubes, cells, and animals. The first-in-human study is the threshold event where, for the very first time, the molecule is given to a person. After years of prediction, it is the moment biology gives its first real answer about how the drug behaves in a human body.

A first-in-human study is, in practice, the opening phase I trial, and it is run with extreme caution. The starting dose is set very low, anchored to the no-observed-adverse-effect level seen in animals and a generous safety factor. Volunteers are usually dosed one or a few at a time, observed closely in a monitored unit, and the dose is escalated only after each level is judged safe. The primary aims are to confirm tolerability and to capture the first human pharmacokinetic data — how the drug rises, spreads, and clears.

This step deserves humility. Animal data reduce but cannot remove the chance of an unexpected human reaction, and history records rare first-in-human studies that caused serious harm, which is exactly why dose escalation is slow and staggered. The principal job here is not to prove the drug works but to learn, safely, whether it is tolerable enough to study further.